outset medical inc - OM
OM
Close Chg Chg %
5.05 0.15 2.97%
Closed Market
5.20
+0.15 (2.97%)
Volume: 256.18K
Last Updated:
Jan 21, 2026, 4:00 PM EDT
Company Overview: outset medical inc - OM
OM Key Data
| Open $5.07 | Day Range 5.02 - 5.36 |
| 52 Week Range 3.10 - 21.98 | Market Cap $91.67M |
| Shares Outstanding 18.15M | Public Float 17.38M |
| Beta 2.07 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$13.00 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.71M |
OM Performance
| 1 Week | -1.89% | ||
| 1 Month | 40.54% | ||
| 3 Months | -64.75% | ||
| 1 Year | -59.23% | ||
| 5 Years | -99.36% |
OM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About outset medical inc - OM
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.
OM At a Glance
Outset Medical, Inc.
3052 Orchard Drive
San Jose, California 95134
| Phone | 1-669-231-8200 | Revenue | 113.69M | |
| Industry | Medical Specialties | Net Income | -127,976,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
OM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.507 |
| Price to Book Ratio | 2.191 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.988 |
| Enterprise Value to Sales | 0.887 |
| Total Debt to Enterprise Value | 2.002 |
OM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 3.192 |
| Total Asset Turnover | 0.386 |
OM Liquidity
| Current Ratio | 5.69 |
| Quick Ratio | 4.382 |
| Cash Ratio | 3.497 |
OM Profitability
| Gross Margin | 34.43 |
| Operating Margin | -94.838 |
| Pretax Margin | -112.135 |
| Net Margin | -112.567 |
| Return on Assets | -43.411 |
| Return on Equity | -170.971 |
| Return on Total Capital | -55.964 |
| Return on Invested Capital | -52.843 |
OM Capital Structure
| Total Debt to Total Equity | 752.668 |
| Total Debt to Total Capital | 88.272 |
| Total Debt to Total Assets | 73.191 |
| Long-Term Debt to Equity | 745.96 |
| Long-Term Debt to Total Capital | 87.485 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Outset Medical Inc - OM
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 102.60M | 115.38M | 130.38M | 113.69M | |
Sales Growth
| +105.47% | +12.45% | +13.00% | -12.80% | |
Cost of Goods Sold (COGS) incl D&A
| 94.99M | 97.54M | 101.38M | 74.55M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 6.18M | 6.28M | 5.81M | 5.73M | |
Depreciation
| 6.18M | 6.28M | 5.81M | 5.73M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +50.85% | +2.68% | +3.93% | -26.47% | |
Gross Income
| 7.61M | 17.83M | 29.00M | 39.14M | |
Gross Income Growth
| +158.36% | +134.40% | +62.62% | +34.98% | |
Gross Profit Margin
| +7.42% | +15.46% | +22.24% | +34.43% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 138.13M | 178.85M | 198.77M | 146.96M | |
Research & Development
| 36.74M | 48.85M | 57.31M | 36.29M | |
Other SG&A
| 101.39M | 130.00M | 141.46M | 110.67M | |
SGA Growth
| +32.27% | +29.48% | +11.14% | -26.06% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 1.37M | 5.55M | - |
EBIT after Unusual Expense
| (130.52M) | (162.39M) | (169.77M) | (113.38M) | |
Non Operating Income/Expense
| 498.00K | 3.29M | 10.17M | 9.76M | |
Non-Operating Interest Income
| 498.00K | 3.29M | 10.17M | 9.76M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.72M | 3.57M | 12.68M | 23.87M | |
Interest Expense Growth
| -40.68% | +107.93% | +255.44% | +88.33% | |
Gross Interest Expense
| 1.72M | 3.57M | 12.68M | 23.87M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (131.74M) | (162.66M) | (172.27M) | (127.48M) | |
Pretax Income Growth
| -8.43% | -23.47% | -5.91% | +26.00% | |
Pretax Margin
| -128.40% | -140.98% | -132.14% | -112.13% | |
Income Tax
| 199.00K | 295.00K | 523.00K | 491.00K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| 199.00K | 295.00K | 523.00K | 491.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (131.94M) | (162.96M) | (172.80M) | (127.98M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (131.94M) | (162.96M) | (172.80M) | (127.98M) | |
Net Income Growth
| -8.60% | -23.51% | -6.04% | +25.94% | |
Net Margin Growth
| -128.59% | -141.24% | -132.54% | -112.57% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (131.94M) | (162.96M) | (172.80M) | (127.98M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (131.94M) | (162.96M) | (172.80M) | (127.98M) | |
EPS (Basic)
| -43.4102 | -50.7536 | -52.2698 | -36.951 | |
EPS (Basic) Growth
| -55.86% | -16.92% | -2.99% | +29.31% | |
Basic Shares Outstanding
| 3.04M | 3.21M | 3.31M | 3.46M | |
EPS (Diluted)
| -43.4102 | -50.7536 | -52.2698 | -36.951 | |
EPS (Diluted) Growth
| -55.86% | -16.92% | -2.99% | +29.31% | |
Diluted Shares Outstanding
| 3.04M | 3.21M | 3.31M | 3.46M | |
EBITDA
| (124.33M) | (154.74M) | (163.96M) | (102.09M) | |
EBITDA Growth
| -9.34% | -24.45% | -5.96% | +37.73% | |
EBITDA Margin
| -121.18% | -134.12% | -125.76% | -89.80% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 13.25 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.758 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -2.657 | |
| Last Quarter’s Earnings | -0.70 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -4.452 | Next Fiscal Year Estimate | -2.399 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 4 | 3 |
| Mean Estimate | -0.76 | -0.78 | -2.66 | -2.40 |
| High Estimates | -0.71 | -0.71 | -2.02 | -2.10 |
| Low Estimate | -0.80 | -0.83 | -3.19 | -2.79 |
| Coefficient of Variance | -5.64 | -7.86 | -18.12 | -14.77 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Outset Medical Inc - OM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Outset Medical Inc - OM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 13, 2026 | Karen Naomi Prange Director | 18,667 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 12, 2025 | Leslie L. Trigg Chair and CEO; Director | 625,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Patrick T. Hackett Director | 1,292,849 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Patrick T. Hackett Director | 1,250,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Patrick T. Hackett Director | 625,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | D. Keith Grossman Director | 192,686 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Brent D. Lang Director | 250,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Karen Ruth Drexler Director | 31,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Nabeel Ahmed Chief Financial Officer | 250,210 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.9 per share | 225,189.00 |
| Feb 20, 2025 | Marc Nash SVP Operations and R&D | 200,764 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.9 per share | 180,687.60 |
| Feb 20, 2025 | John L. Brottem General Counsel | 175,043 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.9 per share | 157,538.70 |